Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

NCT05588648 is registered in ClinicalTrials.gov with MedPacto, Inc. as lead sponsor.

NCT NCT05588648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05588648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Lead sponsor
MedPacto, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 1, 2023
Completion date
February 29, 2028
Enrollment
78 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma